Neuronetics Inc reports results for the quarter ended March 31 - Earnings Summary

• Neuronetics Inc STIM.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -27 cents. The mean expectation of four analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -15 cents to -11 cents per share.

• Revenue rose 83.6% to $31.98 million from a year ago; analysts expected $29.07 million.

• Neuronetics Inc's reported EPS for the quarter was a loss of 21 cents​.

• The company reported a quarterly loss of $12.69 million.

• Neuronetics Inc shares had risen by 22.3% this quarter and gained 179.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 25.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Neuronetics Inc is $7.00

This summary was machine generated from LSEG data May 6 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)